Piper Sandler raised the firm’s price target on Lenz Therapeutics (LENZ) to $67 from $51 and keeps an Overweight rating on the shares. With VIZZ now commercially available, the firm surveyed 25 ECPs to understand potential prescribing and sampling expectations. Acknowledging the need for better treatment options in presbyopia, survey participants anticipated VIZZ to dominate the topical eye drop market. Given that VIZZ is now commercially available, Piper reduces its discount rate to 10%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics Raises $80M Through Stock Sale
- Short Report: TeraWulf short interest at record high despite stock strength
- LENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential
- LENZ Therapeutics Launches FDA-Approved Presbyopia Eye Drop
- Lenz Therapeutics announces U.S. commercial availability of VIZZ